Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Denmark
Sweden
Finland
Norway
Latest
Trending
Followed

BioGaia, Audiocast, Q3'26

By Inderes10/22/2026, 7:30 AM
BioGaia

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Theresa Agnew
00:00 - 09:19

Hello, this is Theresa Agnew, CEO of BioGaia, and we are here to present our Q3 2026 results. So from a financial highlights standpoint, our growth excluding currency effects is 23% for the quarter. Our net sales were 400 million SEK and our EBIT margin was 33%. Overall, our net sales, as we said, have grown 23%, excluding currency effects. And if you look at the regions, our EMEA, Europe, Middle East and Africa region increased by 38% excluding currency effects, and the Americas, which includes Latin America as well as North America, increased by 23%. Sales in Asia Pacific increased by 8%, excluding currency effects. Our overall operating profit for the quarter was around 132 MSEK, which is an increase of 54%, and our EBIT margin was 33% compared to 26% last year in the same quarter. Our overall net sales year-to-date reached 1,214 MSEK, with growth excluding currency effects of 16% and an overall year-to-date adjusted EBIT margin of 31%. So to talk about our strategy, we have three main strategic pillars. Our first is what we call grow the core, which is focused on our core health areas of gut health, oral health, and immune health. Our second area is expansion through direct markets, where over the last five years, we have been taking certain markets direct as subsidiaries and driving growth through those markets. And then finally, breakthrough innovation, where these are probiotics we are working on that will create category opportunities where probiotics are not typically used today. And our foundations are people and culture investing for profitable growth, digital as an enabler, both in the way we go to market with our omnichannel approach, as well as digitizing our business internally to drive more productivity and efficiency; driven by science, which has been a foundation of the company and a very important one for the last 35 years; and sustainable solutions, with a strong focus on driving sustainability in our products as well as how we go to market. In terms of delivering on our strategy for the quarter, in our grow the core area, as you saw, we have had strong growth across pediatrics and adult health segments. This is supported by Protectis drops, Protectis tablets, and Prodentis. We continue investment in consumer and medical marketing to drive growth in our key markets. Specifically, some of our direct markets, where the combination of medical marketing and consumer marketing is used, are driving our growth above the overall category level. We are strengthening our position in oral health, particularly focusing on Prodentis and especially in the US and Canada. For the quarter, we have seen strong growth in Prodentis in those markets. In terms of expansion through direct markets, we continue our development in our direct markets where this has contributed. Our direct markets have contributed to 38% growth in EMEA. We are expanding distribution in France. We started our direct market in 2025, and over the course of the last year, we have been driving distribution dramatically in France, as well as across some key retailers in the UK, where we are now in Holland & Barrett, which is a major retailer in the UK with our Protectis drops in over 600 stores. We continue our focus on strengthening our BioGaia brand. We are expanding our global reach and as I said previously, we have an omnichannel approach where we make our products available in the channels where the consumer wants to buy, and we surround the consumer with digital marketing through social media, video and so forth. In terms of breakthrough innovation, we had an exciting launch this quarter with BioGaia Colus. It adds to our science-based portfolio in adult gut health. Two years ago, we added a product called Gastric Pure Action into Adult Health, and now this year we are adding BioGaia Colus. This is a unique proprietary strain, L. reuteri BG-R59, and it is supported by two independent, randomized controlled clinical trials. Our initial launch has been in the UK, and this will be followed by rollouts across selected markets globally. In terms of our launches, you can see here the launches that happened in the quarter. One of particular interest is that we have launched a new flavor of our Protectis kids tablets with vitamin D. It's a strawberry flavor and this has been well received in the markets where we're launching this. We continue our rollout of our skincare products, our wash as well as body lotion, into the UK. And we've also launched our BioGaia Aldermis, which is our probiotic ointment in Czech Republic and Poland. In addition, we had some key events in the quarter. We announced on August 31st that we are continuing our exclusive distribution agreement with Recordati in Spain and Portugal. As I said, we also announced the launch of our BioGaia Colus product, which is targeted for people to support colon health. And we have some clinical studies, as I said, also in the areas of acute, uncomplicated diverticulitis. And then on September 16th, we announced that we will be hosting a Capital Markets Day in London on December 8th. We will be holding both an in-person event in London, and the presentation will be broadcast live. In terms of our different segments, as you can see here, pediatrics has grown 21% for the quarter, excluding currency effects, and adult health has grown 29% for the quarter. And as you can see over the past quarters, we have had strong growth each quarter in pediatrics as well as adult health, especially adult with strong double-digit growth. Getting a little bit further into the segments. As I said, pediatrics grew 21% and adult health 29% in the quarter. If you look at this year to date, pediatrics is growing 14%, excluding currency effects. And adult health is growing 23%. Specifically in pediatrics, our sales increased mainly in the US, China, and France, and our Protectis drops performed very well in the Americas and EMEA in adult health. Our Protectis tablets increased significantly and sales increased overall in Asia-Pacific and EMEA, mainly in Hong Kong and Italy. And if we now go into more detail in the regions, EMEA grew 38% for the quarter, excluding currency effects. Overall, year-to-date, that puts us at 26% growth for Europe, Middle East, and Africa; Asia Pacific in the quarter grew 8%, and overall that puts us at 2% growth, excluding currency effects. Year to date, the Americas grew 23% in the quarter, and overall year to date, EMEA grew 17%. Some of the highlights for the quarter are that sales increased, mainly in France, Poland, and Germany. We did communicate that we have some quarterly variations for individual orders where customers decided to move some of their orders from Q4 into Q3. For EMEA and Asia Pacific, as I said, the adult health segment grew, but the pediatric segment decreased. Sales for the quarter were mainly in China, South Korea and Japan. And in the Americas, some of the highlights are that both the pediatrics and adult health segments grew. The adult health segment grew, and sales increased mainly in the US, Canada, and Brazil. Overall, this puts us at 74% for pediatrics year to date. And you can see the breakdown of our year-to-date sales: 43% for the Americas, 35% for EMEA and Asia Pacific, and 22% for the rest of the world. I will now turn it over to Alexander Kotsinas to go through the financials in more detail.

Alexander Kotsinas
09:19 - 13:02

Thank you, Theresa. So to summarize, as we heard Theresa mention previously, our sales grew 23% from 327 MSEK to 400 MSEK. Our gross profit grew 20% and our operating profit grew 54%. If we look at the sales bridge, we had a growth of 23%, both including and excluding currency effects. So, basically in the quarter, there were no major currency effects. In terms of the gross margin, we had a gross margin of 73% in the quarter versus 70% for the same quarter last year. And this is mainly due to one to two percentage points lower gross margin in the pediatric segment. And year to date, however, the pediatric margin is flat at 75%. And we have a somewhat lower margin in the Adult Health segment and thereby a year-to-date margin of 72% versus 73%. It is also worth mentioning that in the quarter, we received US tariff refunds from the IEEPA Act totaling 3.2 million SEK, which positively affected the gross margin in the quarter. In terms of the operating expenses, the total operating expenses were 159 million versus 157 million in the same quarter last year, a growth of 2%. On an adjusted basis, the figure remained the same since we did not have any adjustments in the quarter. Our marketing expenses increased mainly due to higher expenses in our subsidiaries. It is also worth mentioning that we have a positive effect in other OPEX of 14 million SEK due to exchange gains on receivables. If we move on to the profit and loss, as we have already mentioned, we have net sales of 400 MSEK, a gross profit of 292 MSEK, and OPEX of 159 MSEK, leading to an EBIT of 133 MSEK, which was 54% higher than in the same period last year. If we look at the EPS, EPS now stands at 1.09 SEK per share versus 0.65 SEK, a growth of 67%. And year-to-date, our profits grew on an adjusted basis by 29% and our EPS grew by 25%. Coming to the cash flow, we have a cash flow from operating activities of about 80 million SEK. The decrease in cash flow from operating activities compared to the same period last year is mainly due to a negative change in working capital, which in turn is due to higher receivables, a slightly higher inventory, and lower payables. These are normal variations, and in the coming quarter we expect these to normalize. So we always see these swings between the quarters. Cash flow from investing activities is also worth mentioning. It was 12 million SEK versus 1 million in the same quarter last year. And this is due to the fact that we are ramping up, as we have explained previously, our investments in BioGaia Production with a new warehouse that is now ongoing, and for year to date, we have investments of about 26 million SEK versus 3 million SEK in the same period last year. So with that, I hand over to Theresa for some concluding remarks.

Theresa Agnew
13:02 - 14:29

In summary, we had a strong Q3 2026 performance with 23% growth, excluding currency effects, and an EBIT margin of 33%. We had double-digit growth across both of our segments. Pediatrics as well as Adult Health. We also had broad-based regional growth with EMEA at 38% growth, Americas at 23%, and Asia Pacific at 8%. We will continue our focus on driving growth in our direct markets and on strengthening our overall product portfolio for our core areas. And one of those ways was launching BioGaia Colus in the quarter. As I said, which is a product specifically focused on supporting colon health, we do have a strong platform for continued profitable growth. We will continue to invest in our science-based innovation in our key markets, both direct markets as well as partner markets, and in building our BioGaia brand globally. As we said, we will host a Capital Markets Day in London on December 8th, and we remain focused on driving our sustainable growth through our strong scientific foundation, expanding our presence of our portfolio in our key markets, and continuing to increase our brand visibility and drive awareness. We will now open it up for questions.

Operator
14:33 - 14:52

If you wish to ask a question, please dial pound five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial pound key six on your telephone keypad. The next question comes from Simon Larsson from Danske Bank. Please go ahead.

Simon Larsson
14:54 - 15:14

Yes. Good morning. Hopefully you can hear me. All right. I would like to start on the EMEA side of the business. And if you could possibly quantify the revenue that was pulled from Q4 into Q3. And also, if it was pediatrics only or also in Adult Health, that's the first one.

Theresa Agnew
15:15 - 15:32

Yes. We will not quantify a specific number, but it is substantial, which is why we are talking about it. So that we give some direction around Q4. It is mainly within the Pediatrics business.

Simon Larsson
15:35 - 15:51

Understood. Understood. And on the two percentage points pediatric gross margin drop. Could you give any more flavor on that? Was it a mix effect or a geographic effect, or was it related to production?

Alexander Kotsinas
15:52 - 16:00

No, it is not really related to any manufacturing costs or anything like that. It is more a mix effect between both geographies and products.

Simon Larsson
16:03 - 16:25

Understood. The final one maybe on APAC, we have had a couple of softer quarters in APAC, but now I read it like you see drops growing in China. So how should we expect this to pan out in Q4? Or should we expect orders to pick up again in the APAC region? What can you see right now?

Theresa Agnew
16:26 - 16:37

Yeah. So in terms of Q4, we do expect orders to pick up in the Asia Pacific region. So we anticipate strong results for Asia Pacific in Q4.

Simon Larsson
16:40 - 16:41

Understood. Thanks so much.

Operator
16:48 - 16:52

The next question comes from Matthias Haggblom from Nordea. Please go ahead.

Matthias Haggblom
16:55 - 17:53

Thanks so much for taking my question. I have two, please. So firstly, on the pull-forward orders in EMEA, did those partly explain the soft gross margin because again, it was on the low side versus consensus expectations, not least if we adjust for the IEEPA tariff refund. Sometimes we know from history that these lumpy orders come at a lower margin. So any clarification on that, Alex. Regarding the product and geographical mix. I'm curious to hear if it was perhaps even more so driven by this one. And then, secondly, on OPEX, you state 2% OPEX growth. But that of course includes the help from the FX gain. So if I look at what I would call true OPEX, selling, admin, or R&D, it is up year over year 13%; that may not be a problem when you're growing top line so fast, but perhaps help me think about OPEX expansion going forward, as we can't count on FX gains for every quarter. Thanks so much.

Alexander Kotsinas
17:55 - 18:49

Okay, so when it comes to the gross margin, no, I would not say it's those EMEA orders in themselves. I mean, normally, we have quite stable and good margins in EMEA. So, it is more like a mix, as I said previously, between the regions and the products that we saw in the quarter. Yeah. Then about the OPEX. Yes, of course. I mean, we do have quite a strong growth in the quarter. And that is due to a lot of activities we are doing in marketing and sales. There is some correlation, of course, between marketing and sales costs and the actual sales that we achieve from those activities. That is why we see quite high growth in the marketing and sales costs due to that correlation, so to speak.

Operator
18:57 - 19:01

The next question comes from Christopher Lilienberg from DNB Carnegie. Please go ahead.

Simon Larsson
19:04 - 19:20

Yeah. Coming back. Yeah. A few questions coming back to this previous question on operating costs, but isn't it true that you also have some selling costs correlated to the actual sales number in the quarter to distributors, etc.

Alexander Kotsinas
19:25 - 19:50

Yes. As I mentioned previously. That is correct. We do have some sales costs. That actually leads to sales in the same period, so to speak. So there is a correlation between sales and costs. Yes of course. Of course, some of the costs within that line are more fixed and do not depend on sales, but some costs are definitely variable. As we have quite high sales, the costs will increase as well.

Simon Larsson
19:52 - 20:17

Yeah. My second question relates to what you said about the Asia Pacific, and that you expect it to be strong in Q4. You had very strong growth in the Pacific in Q4 last year. But do you mean that despite that, we should expect strong year-over-year growth in Asia Pacific this last quarter of the year?

Theresa Agnew
20:18 - 20:36

Yes. Yes. We would expect in Q4 to have strong year-over-year growth, even from the quarter last year, but that will balance out across the regions. But for Asia Pacific, we expect to have strong year-on-year growth in the quarter.

Simon Larsson
20:39 - 20:53

Great. Maybe specifically, given that you are back to growth now, could you explain a little bit the market outlook for key markets such as China, Japan, and Korea? Maybe.

Theresa Agnew
20:54 - 22:02

Sure. Overall, in terms of China, that market in particular is seeing a slowing economy, which does impact consumer spending. Overall compared to last year, that market dynamic has changed. Our business is continuing to grow at a healthy rate, but not as high as it was previously. Specifically in China. In Korea, we are seeing our business continue to grow in a healthy way across our portfolio. The majority of our sales in Korea are in Pediatrics. In Japan, our main business is Prodentis oral health. So we are seeing strong growth of Prodentis in Japan. And we expect that to continue. We are putting some emphasis on our pediatric business in Japan because it is currently very small. So we are looking at driving growth there more in the future.

Simon Larsson
22:04 - 22:23

Great. And finally, the strong adult health growth in Asia Pacific and America, as you mentioned, Prodentis in Japan. Is this the main product driving this strong growth in both those two regions or are there other products as well.

Theresa Agnew
22:24 - 22:49

It is Prodentis in the Americas region, specifically the US and Canada, that is seeing strong growth, as well as Japan as we mentioned, but our Protectis chewable tablets also grew well in the quarter, specifically in Hong Kong. We have a large business for our chewable tablets in Hong Kong. So for the quarter, that was stronger.

Simon Larsson
22:50 - 22:52

Okay, great. Thank you.

Operator
22:57 - 23:11

As a reminder, if you wish to ask a question, please dial the pound key on your telephone keypad. The next question comes from Philip Wetterqvist from SB1 Markets. Please go ahead.

Philip Wetterqvist
23:13 - 24:01

Good morning, Theresa and Alexander. One question on sales and marketing costs. I noticed that. It grew about 70% in the quarter. And compared to gross profit, which grew about 19%. And in order to reach the 34% EBIT margin target, it presumably requires selling expenses to grow materially slower than gross profit. So how confident are you that you can achieve that operating leverage? And if you cut back on sales and marketing costs, are you still confident that you will be able to grow the top line at the same rate as you have been doing in the last few years?

Theresa Agnew
24:01 - 24:52

Yes. Our long-term target is 34% for EBIT margin. And so we do not give specific guidance, but we anticipate getting to the long-term target over the next couple of years. And we do anticipate continuing to look at our marketing and selling costs to ensure that we are able to reach the EBIT margin. Now, we have delivered on this as we have reduced our sales and marketing costs. This is overall consistent with the larger investments we made last year. And so for markets such as the US, we are continuing to drive growth. So we do feel that we can continue to drive growth even with a smaller amount of sales and marketing costs.

Philip Wetterqvist
24:55 - 25:07

Could you give us some color on where the incremental sales and marketing spend is going as of right now, like between Adult Health and Pediatrics, and the regional split between Americas, EMEA, and APAC?

Theresa Agnew
25:08 - 25:50

Yeah. It is very much dependent on the market and their products. So when we talk about the US and Canada. We focus on our baby drops business as well as Prodentis. So, the expenses will go towards those products in those regions. I would say our marketing costs are going to mainly be around the Americas as well as EMEA. Because in EMEA, we've added some direct markets. We have added France, Germany, and Austria. So we will continue to invest in those direct markets.

Philip Wetterqvist
25:53 - 25:54

All right. That is clear. Thank you.

Operator
25:58 - 26:05

There are no more questions at this time. So I hand the conference back to the speakers for any closing comments.

Theresa Agnew
26:06 - 26:14

That concludes our Q3 2026 results. Thank you for attending, and we will talk to you next quarter.

Continue to the webcast
Lundbeck - Præsentation af delårsrapport for Q3 2026
Language: Danish11/12/2026, 12:00 PM
H. Lundbeck A/S ventes at offentliggøre sin delårsrapport for Q3 2026 den 11. november 2026. Dagen efter, den 12. november kl. 13.00, vil Jens Høyer, Vice President & Head of Investor Relations, præsentere resultaterne og svare på spørgsmål fra publikum i et live online event.
Wirtek - Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 10:00 AM
Wirtek is expected to release its Q3 2026 interim report on 11 November 2026. The next day at 11.00 CET, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Rovsing - Præsentation af Interim Management Statement for Q1 2026/27
Language: Danish11/11/2026, 12:00 PM
Rovsing ventes at offentliggøre sin Interim Management Statement for Q1 2026/27 den 10. november 2026. Den 11. november kl. 13.00 vil ledelsen præsentere kvartalets tal, give en status på udviklingen i forretningen samt følge op på de seneste selskabsnyheder. Præsentationen efterfølges af en Q&A-session.
DADC - Præsentation af handelsopdatering for Q3 2026
Language: Danish11/5/2026, 8:30 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Danish Aerospace and Defence Company (DADC) ventes at offentliggøre sin handelsopdatering for 3. kvartal 2026 den 4. november 2026. Dagen efter, den 5. november kl. 09.30, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
Boozt AB, Audiocast, Q3'26
Language: English11/3/2026, 8:30 AM
Herman Landin Thank you and good morning to all. Welcome to our Q3 2026 presentation. So, let's turn to the first slide, please. We will follow our usual agenda. I'll take you through the highlights a…
NORDEN – Presentation of Q3 2026
Language: English10/29/2026, 9:30 AM
NORDEN is expected to release its Q3 2026 results on 29th October 2026. The same day at 10.30am, management will present the results in an online event followed by a Q&A.
Agillic – Præsentation af kvartalsrapporten for Q3 2026
Language: Danish10/22/2026, 8:00 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Agillic offentliggør kvartalsrapporten for Q3 2026 den 22. oktober 2026. Samme dag kl. 10:00 vil selskabets CEO Christian Samsø præsentere resultaterne, gennemgå forventningerne til resten af 2026, give en opdatering på markedsforholdene og besvare spørgsmål ved et online live-event.
Nordea third-quarter results 2026
Language: English10/15/2026, 8:00 AM
Head of Investor Relations Good morning and welcome to Nordea's third-quarter 2026 results. Nordea's third-quarter 2026 results. I am your Head of Investor Relations. As usual, we will start with the…
GreenMobility - Presentation of the Q3 2026 Trading Statement
Language: English10/14/2026, 11:00 AM
GreenMobility is expected to release its Q3 2026 Trading Statement on 8 October 2026. On 14 October at 13:00 CEST, CEO Kasper Gjedsted will present the figures and answer questions in a live online event.
Rovsing – Præsentation af årsrapport 2025/26
Language: Danish9/28/2026, 9:00 AM
Rovsing ventes at offentliggøre årsrapporten for regnskabsåret 2025/26 den 25. september 2026. Den 28. september kl. 11.00 vil ledelsen præsentere årets resultater, give en status på udviklingen i forretningen samt kigge frem mod 2026/27. Præsentationen efterfølges af en Q&A-session
Danish Aerospace and Defence Company – Præsentation af H1 2026 resultater
Language: Danish8/25/2026, 8:00 AM
Danish Aerospace and Defence Company (DADC) ventes at offentliggøre selskabets rapport for H1 2026 den 24. august 2026. Dagen efter, den 25. august kl. 10.00, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
North Media – Præsentation af regnskabet for 2. kvartal 2026
Language: Danish8/21/2026, 12:00 PM
Tilmeld dig North Media’s præsentation af regnskabet for 2. kvartal 2026 – fredag d. 21. august 2026 kl. 14.00. Se med når ledelsen i North Media gennemgår kvartalsregnskabet der offentliggøres dagen før, og hvordan første halvår af 2026 er forløbet, samt svarer på spørgsmål.
Wirtek – Presentation of Q2 2026 Interim Report
Language: English8/14/2026, 9:00 AM
Wirtek is expected to release its Q2 2026 interim report on 12 August 2026. Friday 14 August at 11.00 CEST, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Boozt AB, Audiocast, Q2'26
Language: English8/14/2026, 7:30 AM
Herman Thank you. Good morning to all, and welcome to our Q2 2026 webcast. So let's turn to the first slide, the agenda for today's presentation. We will follow our usual agenda. I'll take you through…
NORDEN – Presentation of the quarterly report for Q2 2026
Language: English8/13/2026, 8:30 AM
NORDEN is set to release its quarterly report for Q2 2026 on the morning of Thursday 13 August 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q2'26
Language: English8/12/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on second quarter 2026 results. My name is Mirko Hurmerinta, the interim Head of IR at Sampo. I am joined on the c…
Nordea half-year results 2026 webcast
Language: English7/16/2026, 8:00 AM
Ilkka Good morning and welcome to Nordea's second quarter 2026 results. I am Ilkka, Head of Investor Relations. As usual, we'll start with the presentation by Group CEO Frank Vang-Jensen, followed by…
NORDEN – Presentation of the quarterly report for Q1 2026
Language: Danish5/6/2026, 8:30 AM
NORDEN is set to release their quarterly report for Q1 2026 on the morning of Wednesday 6 May 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q1'26
Language: English5/6/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on first quarter 2026 results. My name is Mirko Hurmerinta and I am the interim Head of Investor Relations at Samp…
Boozt AB, Audiocast, Q1'26
Language: English4/24/2026, 7:30 AM
Herman Good morning and welcome to our presentation of our Q1 2026 report. Let's just go to the agenda slide. We will have the usual agenda for the presentation. And I will present the highlights of t…